Trimi Health Review

Trimi Health (trytrimi.com) — Provider Profile

⚠️ April 2026 Warning — Compounding-Only, Supply at Risk: Trimi Health offers compounded GLP-1 medications only, with no branded alternatives. The FDA removed tirzepatide from the shortage list in October 2024 — Trimi has acknowledged it can no longer provide compounded tirzepatide. Compounded semaglutide supply is declining under active FDA enforcement, with ongoing FDA enforcement actions against 503B outsourcing facilities. Trimi has not announced any branded medication pivot. New patients should strongly consider alternatives with branded medication options before committing here. Existing patients should plan for a potential supply disruption.

Overview

Trimi Health is a compounding-only GLP-1 telehealth platform built around aggressive pricing — $99/month for compounded semaglutide, $125/month for compounded tirzepatide — with a fully async consultation model. The company markets itself as accessible and affordable, partnering with Beluga Health for provider services and compounding pharmacies VialsRx and Greenwich RX for fulfillment.

April 2026 market context: Trimi's business model — compounding-only, no branded alternatives — faces mounting pressure as FDA enforcement actions continue against 503B outsourcing facilities (503B compliance deadlines passed in 2025). Compounded tirzepatide is already unavailable here (FDA removed from shortage list October 2024). Compounded semaglutide supply is declining. Trimi has no branded medication offering and has not announced any pivot to brand alternatives. Trustpilot reviews show a troubling bimodal pattern — 59% five-star but 37% one-star — with specific complaints about unauthorized plan changes, unresponsive customer service, and medication quality concerns. Scam Detector rates the site 55.2/100 (caution). The company has not publicly disclosed its headquarters or leadership team.

Medications Offered

Compounded only — no branded alternatives available:

• Compounded semaglutide — GLP-1 receptor agonist; weekly injection; non-FDA-approved
• Compounded tirzepatide — no longer available per company's own acknowledgment following FDA enforcement

Trimi does not offer brand-name Wegovy, Ozempic, Mounjaro, Zepbound, or orforglipron. This is a critical limitation: with compounded semaglutide supply declining under ongoing FDA enforcement actions, there is no reliable medication pathway for new patients through this platform.

Compounding pharmacy partners: VialsRx and Greenwich RX (USP <797> sterile standards). Zofran offered for nausea management.

Pricing

Commitment discounts available (3-, 6-, 12-month). One user reported ~$122/month on a 12-month semaglutide plan. Flat-rate regardless of dose. HSA/FSA eligible.

Note: These prices are moot if compounded medication supply cannot be consistently fulfilled. Patient complaints include unauthorized switches from monthly to quarterly billing without consent.

States Served

Trimi claims to serve all 50 US states with nationwide shipping. Providers through Beluga Health are licensed in patients' respective states.

Insurance

Cash-pay only. No commercial insurance, Medicare, or Medicaid accepted. HSA/FSA cards accepted.

Consultation Process

Model: Fully async — no video consultation required.

1. Complete online health questionnaire (5–10 minutes); BMI 30+ required, or BMI 22+ with a weight-related condition
2. Board-certified physician reviews within 24 hours (same-day prescription possible)
3. Medication delivered in 2–5 days via expedited shipping
4. Ongoing support through 24/7 patient portal messaging

Provider network: Beluga Health (board-certified physicians licensed nationally).

Pros

• Very low headline pricing ($99/mo semaglutide, $125/mo tirzepatide when available)
• Flat-rate pricing — same cost regardless of dosage tier
• All-inclusive: consultation, medication, and shipping bundled
• Claims to serve all 50 states
• Fast turnaround: same-day prescription possible, 2–5 day delivery
• HSA/FSA eligible

Cons

• Compounding-only platform — no branded alternatives. With compounded tirzepatide already unavailable and semaglutide supply declining under FDA enforcement, there is no reliable medication pathway for new patients
• Compounded tirzepatide no longer available (FDA removed from shortage list October 2024)
• Trustpilot: 3.5/5 stars with 37% one-star reviews — unusually high negative rate; specific complaints include unauthorized billing changes, unresponsive customer service, medication quality concerns
• No transparency on company headquarters, founding year, or leadership team
• Scam Detector rating: 55.2/100 (caution level)
• Trimi has not responded to negative reviews on Trustpilot
• No video consultation option
• No lab testing, coaching, dietitian access, or wraparound care
• Fully async model with no in-person touchpoints
• Limited company history and very small scale (claimed 16,400+ patients — small vs. major platforms)

Best For

We do not recommend Trimi Health for new patients as of April 2026. The compounding-only model is at high regulatory risk under ongoing FDA enforcement actions (503B compliance deadlines already passed in 2025), compounded tirzepatide is already unavailable, the platform has no branded medication pivot, and the Trustpilot review pattern — including specific complaints about unauthorized billing and refund manipulation — raises enough concerns to steer patients elsewhere.

For patients attracted to Trimi's low $99/month price point: oral Wegovy at $149/month (introductory rate through ~April 15) or brand Zepbound at $299/month via LillyDirect are the most comparable alternatives. If orforglipron is approved April 10 at the announced $149/month price, it would represent the closest cash-pay branded alternative to Trimi's compounded pricing.

Editorial Verdict

Trimi entered the market as a budget competitor in a crowded compounded GLP-1 field. The $99/month entry price was among the most aggressive available — genuinely accessible to price-sensitive patients. But the model had a single load-bearing assumption: that compounded GLP-1 supply would continue. It didn't.

The FDA's removal of tirzepatide from the shortage list (October 2024) and ongoing enforcement against 503B outsourcing facilities (compliance deadlines already passed in 2025) have put Trimi's supply base at severe risk. Unlike platforms that are actively transitioning to branded medication menus (Ro, Hims, LifeMD), Trimi has not publicly announced any branded alternative. The platform that claimed to serve 16,400+ patients has no clear product pathway beyond the next few months.

Separately, the Trustpilot review pattern is concerning independent of the supply issue. A 37% one-star rate with specific allegations of unauthorized billing changes, poor customer service, and medication quality questions — and zero responses from the company — reflects either operational dysfunction or bad faith. Scam Detector's 55.2/100 caution rating compounds this concern.

Bottom line as of April 2026: Trimi Health cannot be recommended for new patients. Compounded tirzepatide is already gone, compounded semaglutide supply is under active enforcement pressure, they have no branded alternative, and independent review signals raise enough operational concerns to avoid the platform entirely. Patients who value Trimi's price point should look at oral Wegovy at $149/month introductory pricing, or wait to see if orforglipron launches at $149/month post-April 10 PDUFA — both provide branded, FDA-approved options at a comparable cash price without compounding risk.

Related Content

• Best GLP-1 Weight Loss Programs 2026 — All providers ranked
• FDA Enforcement Tracker for Telehealth GLP-1 Providers — Compounding crackdown tracker
• GLP-1 Pricing Breakdown by Provider — Side-by-side cost comparison
• How to Switch GLP-1 Providers in 2026 — Provider transition guide
• Compounded vs Brand GLP-1 FAQ — Understanding the differences